Literature DB >> 10585207

Improving the nicotinic pharmacophore with a series of (Isoxazole)methylene-1-azacyclic compounds: synthesis, structure-activity relationship, and molecular modeling.

J E Tønder1, J B Hansen, M Begtrup, I Pettersson, K Rimvall, B Christensen, U Ehrbar, P H Olesen.   

Abstract

A series of (isoxazole)methylene-1-azacyclic compounds was prepared. The compounds were tested for affinity to central nicotinic acetylcholine receptors (nAChRs) and central muscarinic receptors. The compounds covered a broad range of affinities for the nAChRs (IC(50) = 0.32 to >1000 nM), with selectivities for the nAChRs over the muscarinic receptors in the range of 3-183. The high-affinity compound (Z)-26 (3-(4-methyl-5-isoxazolyl)methylene-1-azabicyclo[2.2. 2]octane, IC(50) = 3.2 nM) having only one energy minimum was used as the reference structure in a computational study. This ligand has enabled definition of an important distance parameter, and the existence of this parameter was supported by showing that other potent nicotinic ligands (for example, nicotine and epibatidine) fit the model.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10585207     DOI: 10.1021/jm9910627

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  7 in total

1.  An improved nicotinic pharmacophore and a stereoselective CoMFA-model for nicotinic agonists acting at the central nicotinic acetylcholine receptors labelled by.

Authors:  J E Tønder; P H Olesen; J B Hansen; M Begtrup; I Pettersson
Journal:  J Comput Aided Mol Des       Date:  2001-03       Impact factor: 3.686

2.  Identification of novel α4β2-nicotinic acetylcholine receptor (nAChR) agonists based on an isoxazole ether scaffold that demonstrate antidepressant-like activity.

Authors:  Li-Fang Yu; Werner Tückmantel; J Brek Eaton; Barbara Caldarone; Allison Fedolak; Taleen Hanania; Dani Brunner; Ronald J Lukas; Alan P Kozikowski
Journal:  J Med Chem       Date:  2012-01-04       Impact factor: 7.446

3.  The twin drug approach for novel nicotinic acetylcholine receptor ligands.

Authors:  Isabelle Tomassoli; Daniela Gündisch
Journal:  Bioorg Med Chem       Date:  2015-06-20       Impact factor: 3.641

Review 4.  Nicotinic agonists, antagonists, and modulators from natural sources.

Authors:  John W Daly
Journal:  Cell Mol Neurobiol       Date:  2005-06       Impact factor: 5.046

5.  Computational analysis of the binding ability of heterocyclic and conformationally constrained epibatidine analogs in the neuronal nicotinic acetylcholine receptor.

Authors:  Elena Soriano; José Marco-Contelles; Inés Colmena; Luis Gandía
Journal:  Mol Divers       Date:  2009-05-29       Impact factor: 2.943

Review 6.  Epibatidine: impact on nicotinic receptor research.

Authors:  Małgorzata Dukat; Richard A Glennon
Journal:  Cell Mol Neurobiol       Date:  2003-06       Impact factor: 5.046

Review 7.  Computer-aided Drug Design Applied to Parkinson Targets.

Authors:  Hamilton M Ishiki; Jose Maria Barbosa Filho; Marcelo S da Silva; Marcus T Scotti; Luciana Scotti
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.